Navigation Links
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Date:9/18/2007

ith HIV medications and had a viral load greater than 5,000 copies. Overall the study population had a mean baseline viral load of 4.85 log10 copies per mL and a median CD4+ cell count of 225 cells per cubic millimeter.

Patients were randomized to receive PREZISTA/r 800 mg/100 mg once daily (n=343) or, based on approved dosing in each country, either lopinavir/r 800 mg/200 mg once daily or 400 mg/100 mg twice daily (n=346), plus a background regimen of tenofovir and emtricitabine once daily. Patient randomization was stratified based on viral load and CD4+ cell count.

ARTEMIS: 48-week study results

In the per-protocol analysis of 689 patients, among patients randomized to the once-daily PREZISTA/r arm (n=343) vs. the lopinavir/r arm (n=346), the 48-week analysis showed that:

-- 84 percent of patients in the PREZISTA/r arm reached an undetectable

viral load (<50 copies/mL) vs. 78 percent of patients in the

lopinavir/r arm.

-- The median change in CD4+ cell count from baseline was similar between

the PREZISTA/r and lopinavir/r arms (137 cells per cubic millimeter vs.

141 cells per cubic millimeter).

ARTEMIS: Safety findings

-- In the two study arms the adverse events at least Grade 2 in severity

included diarrhea, nausea and rash. Diarrhea was 4.1 percent in the

PREZISTA/r arm vs. 9.8 percent in the lopinavir/r arm. Nausea was 1.7

percent in the PREZISTA/r arm vs. 2.9 percent in the lopinavir/r arm.

Rash was 2.6 percent in the PREZISTA/r arm vs. 1.2 percent in the

lopinavir/r arm.

-- Incidence of Grade 3-4 lipid-related adverse events reported in

PREZISTA/r arm were 1.7 percent vs. 5.2 percent in the lopinavir/r arm.

-- In both treatment arms there was a low incidence of discontinuation.

Discontinuations due to adverse events were 3.4 percent in the

PREZISTA/r arm vs. 6.9 percent in the lopinavir/r arm.


'/>"/>
SOURCE Tibotec Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... März 2015  Die National Association of ... 2015 an Zulassungsanträge für Domainnamen mit der ... Seit dem Start des .Pharmacy Top-Level Domain- ... .pharmacy-Domainnamen zugelassen, die für die vorherigen, begrenzten ... Die NABP startete .pharmacy TLD, um Verbrauchern ...
(Date:3/26/2015)... profiled MJ Freeway , a business software company for ... Did It," which features companies with unique paths to success. ... illustrates how two tech entrepreneurs from Telluride, Colorado ... industry. Writer ... Jessica Billingsley used their experience in the technology ...
(Date:3/26/2015)... a loved relative suffering from cancer - and you ... too expensive. The Austrian Centre of Industrial Biotechnology (acib) ... costs of highly valued drugs significantly. ... pathogens or cancer cells. Therapeutic antibodies are used as ... diseases such as multiple sclerosis. According to "bccresearch.com" the ...
Breaking Medicine Technology:Alle abgebenden Apotheken berechtigt, um ab dem 1. April 2015 .Pharmacy-Domainnamen zu beantragen 2MJ Freeway, Industry-Leading Software Solution for Cannabis Businesses, Featured in CNBC Special "How I Did It" 2World's First Method for Continuous Purification of Valuable Antibodies 2
... American Academy ... of Dermatology, FREEPORT, N.Y., Feb. ... diols (BMTds) to reduce,collagenese MMP-1 secretion and increase collagen production is dependent,on ... Session at the 66th Annual Meeting of the American Academy of,Dermatology in ...
... Provides Update on DARA Program,s Ongoing Phase 2a ... ... PCOP ), an innovator in the discovery and development of novel,small ... compound from its internal CCR1 discovery,program. PS031291 is a potent and ...
Cached Medicine Technology:AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling 2Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development 2Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development 3Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development 4
(Date:3/26/2015)... Md. (PRWEB) March 26, 2015 ... than $11.3 billion in 2014, according to an ... , The Annapolis-based healthcare real estate (HRE) data ... board members and two new Gold-Level Partners: Harrison ... Investment Services. , MOB transactions still going strong, ...
(Date:3/26/2015)... 2015 Pacific Medical LLC, the leader ... be featured on Innovations with Ed Begley Jr, which ... The episode will repeat on local cable channels ... Pacific Medical home page at: http://www.pacificmedicalsupply.com . ... is reassuring to trust the integrity of the medical ...
(Date:3/26/2015)... On March 5, 2015, Portland Trail ... for the season with a torn Achilles tendon in ... Blazers were competing against Dallas, and was confirmed via ... Silva, M.D., who has treated many professional athletes, voiced ... could be prevented. , "Part of the problem ...
(Date:3/26/2015)... In the key developed markets, the hypertension market value ... to decrease through 2020 at a negative CAGR (0.9%) to ... to 2017 at a 2.6% CAGR and a decline thereafter. ... surging penetration of fixed-dose combination drugs like Azor, Amturnide, Exforge ... and Tekamlo), a hike in the prevalence population to 190 ...
(Date:3/26/2015)... March 26, 2015 In preparation for ... Fitness Revolution, founded by Samir Becic, has issued ... own personal health and fitness, as well as their ... The list includes Sen. Ted Cruz, who has officially ... as all other politicians who have shown interest in ...
Breaking Medicine News(10 mins):Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 2Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 3Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 4Health News:Pacific Medical Featured on the Discovery Channel 2Health News:Pacific Medical Featured on the Discovery Channel 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3
... they are admitted to hospital may be one way to ... today’s BMJ. ,Recent data published by the Health ... 7,000 inpatients have MRSA infections and more than 50,000 inpatients ... of C difficile rose by 5.5% in 2006, whereas MRSA ...
... by blocking the lifesaving effects of aspirin//, a new study ... monstrous," Michael Farkouh, director of clinical trials at Mount Sinai ... ,“Ibuprofen is relatively safe except when we give it ... Farkouh says. "But when given with aspirin, we do we ...
... couple of months, 100,000 doses of the country's first vaccine ... developed it has found no takers //and the expiry date ... year that the High Security Animal Disease Laboratory (HSADL) here ... about 100,000 doses of the vaccine, each costing just 27 ...
... mammograms are more likely to interpret a benign growth ... and experience," and CAD systems do not help detect ... systems use complex algorithms to identify "suspicious" areas of ... which cost $50,000 to $175,000, were approved by FDA ...
... The Food and Drug Administration (FDA) today warned consumers ... Chews and Dog Chews manufactured// and distributed by T.W. ... have the potential to be contaminated with Salmonella, which ... if there is cross contamination, in people, especially children, ...
... Foundation on Wednesday announced that it will spend $500 ... address childhood obesity//, particularly targeting minority children, who are ... ,Nearly 25 million children under age 18 are considered ... medical expenses, according to the foundation. ,The ...
Cached Medicine News:Health News:Ibuprofen Risky for Heart Patients? 2Health News:100,000 Bird Flu Vaccine Doses to Be Destroyed 2
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With polished ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With reinforced ...
Medicine Products: